Altman, E.G., Hedeker, D.R., Janicak, P.G., et al. The clinician-administered rating scale for mania (CARS-M): development, reliability, and validity. Biol Psychiatry. 1994;36:124–3l.CrossRefGoogle ScholarPubMed

Boadie, W.D., Thase, M.E., Wun, C.C., et al. A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: the importance of academic sites. Neuropsychopharmacology. 2012;1–7:2.Google Scholar

Bowden, C. L., Strategies to reduce misdiagnosis of bipolar depression. Psychiatr Serv.· 2001;52(1):51–5.CrossRefGoogle ScholarPubMed

Bowden, C.L. Bipolar pathophysiology and development of improved treatments. Review and recommendations for innovative studies. Brain Res. 2008;1235:92–7.CrossRefGoogle Scholar

Bowden, C.L., Brugger, A.M., Swann, A.C., et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA. 1994;271:918–24.CrossRefGoogle ScholarPubMed

Bowden, C.L., Calabrese, J.R., McElroy, S.L., et al. A randomized, placebo-controlled 12 month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder Arch Gen Psychiatr. 2000;57:481–9.CrossRefGoogle ScholarPubMed

Bowden, C.L., Tohen, M., Mintz, J., et al. Development of novel integrative multistate measures of efficacy, tolerability and functional status in maintenance clinical trials for bipolar disorder. Annual Meeting of the ACNP, Kona, Hawaii, December 2011.Google Scholar

Calabrese, J.R., Bowden, C.L., McElroy, S.L., et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry. 1999;156:1019–23.CrossRefGoogle ScholarPubMed

Calabrese, J. R., Suppes, T., Bowden, C. L., et al. A double-blind placebo-controlled prophvlaxis study of lamotrigine in rapid cycling bipolar disorder. J Clin Psychiatry. 2000;61:841–50.CrossRefGoogle Scholar

Calabrese, J.R., Bowden, C.L., Sachs, G., et al. A placebo–controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder J Clin Psychiatr. 2003;64:1013–24.CrossRefGoogle ScholarPubMed

Cassidy, F., Forest, K., Murry, E., et al. A factor analysis of the signs and symptoms of mania.·Arch Gen Psychiatr. 1998;55:27–32.CrossRefGoogle ScholarPubMed

Dilsaver, S.C., Benazzi, F., Akiskal, H.S. Mixed states: the most common outpatient presentation of bipolar depressed adolescents? Psychopathology. 2005;38:268–72.CrossRefGoogle ScholarPubMed

Fibiger, H.C. Psychiatry, the pharmaceutical industry and the road to better therapeutics. Schizophr Bull. 2012;38:649–50.CrossRefGoogle ScholarPubMed

Frye, M.A., Ketter, T.A., Kimbrell, T.A., et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 2000;20:607–14.CrossRefGoogle ScholarPubMed

Geller, B., Zimerman, B., Williams, M., et al. Bipolar disorder at prospective follow-up of adults who had prepubertal major depressive disorder. Am J Psychiatry. 2001;158:125–7.CrossRefGoogle ScholarPubMed

Gould, T.D., Chen, G., Manji, H.K. In vivo evidence in the brain for lithium inhibition of glycogen synthesase kinase-3. Neropsychopharmacology. 2004;29:32–8.Google Scholar

Grunze, H., Erfuth, A., Marcuse, A., et al. Tiagabine appears not to be efficacious in acute mania. J Clin Psychiatr. 1999;60:759–62.CrossRefGoogle Scholar

Hollander, E., Lopez, A.A., Bienstock, C.A., et al. A preliminary double-blind, placebo controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatr. 2001:199–2003.CrossRefGoogle ScholarPubMed

Hollander, E., Tracy, K.A., Swann, A.C., et al. Divalproex in the treatment of impulsive aggressive: efficacy in cluster B personality disorders. Neuropsychopharmacology. 2003;28:1186–97.CrossRefGoogle ScholarPubMed

Kendler, K.S. A gene for…the nature of gene action in psychiatric disorders. Am J Psychiatr. 2005;162: 1243–595.CrossRefGoogle Scholar

Kessler, R.C., Chiu, W.T., Demler, O., et al. Prevalence, severity, and comorbidity of 12-month DSM·IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatr. 2005;62:590–2.Google ScholarPubMed

Kupfer, D.J., Frank, E., Grochocinski, V.J., et al. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry. 2002;63:120–5.CrossRefGoogle Scholar

Leon, A.C. Evolution of psychopharmacology trial design and analysis: six decades in the making. J Clin Psychiatry. 2011;72:331–40.CrossRefGoogle Scholar

Mitchell, P.B., Hadzi-Pavlovic, D., Evoniuk, G., et al. Factor analytic study in bipolar depression, and response to lamotrigine. CNS Spectrum. 2013;18:214–24.CrossRefGoogle ScholarPubMed

Pande, A.C., Crockatt, J.G., Janney, C.A., et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord. 2000;2:249–55.CrossRefGoogle ScholarPubMed

Paul, S.M., Mytelka, D.S., Dunwiddie, C.T., et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature reviews. Drug Discov. 2010;9:203–14.CrossRefGoogle Scholar

Stahl, S.M. Dopamine system stabilizers, aripiprazole and the next generation of antipsychotics: illustrating their mechanism of action. J Clin Psychiatr. 2001;62:923–4.Google ScholarPubMed

Swann, A.C., Janicak, P.L., Calabrese, J. R., et al. Structure of mania, depressive, irritable, and psvchotic clusters with distinct course of illness in randomized clinical trial participants. J Affect Disord. 2001;67:123–32.CrossRefGoogle ScholarPubMed

Swann, A.C., Bowden, C. L., Calabrese, J.R., et al. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology. 2002;26:530–6.CrossRefGoogle ScholarPubMed

Tohen, M., Goldberg, J. F., Gonzalez-Pinto Arrillaga, A.M.., et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatr. 2003;60(12):1218–26.CrossRefGoogle ScholarPubMed

Tohen, M., Chengappa, K. N., Suppes, T., et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser vs mood stabiliser alone. Br J Psychiatry. 2004a; 18–1:337-3-15.Google Scholar

Tohen, M., Vieta, E., Calabrese, J.R., et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatr. 2004b;61:1079–88.Google Scholar

Wang, P.W., Yang, Y., Chandler, R.A., et al. Adjunctive zonisamide for weight loss in euthymic bipolar disorder patients: a pilot study. J Psychiatr Res. 2008;42: 451–7.CrossRefGoogle ScholarPubMed

Williams, J. B., Gibbon, M., First, M.B., et al. The structured clinical interview for DSM-111-R (SCID) II. multisite test-retest reliability·. Arch Gen Psychiatry. 1992;9(8):630–6.Google Scholar